Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions

Taketa, Kazuhisa; Sekiya, Chihiro; Namiki, Masayoshi; Akamatsu, Koichi; Ohta, Yasuyuki; Endo, Yasuo; Kosaka, Kiyowo

doi:10.1016/0016-5085(90)91034-4

Cited by 208 publications

(134 citation statements)

References 23 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…AFP is also increased in benign liver diseases such as chronic hepatitis and cirrhosis, and this makes the diagnosis of early-stage HCC by serum levels of AFP difficult. 13,14 On the other hand, prothrombin, a glucose protein with 72 kd of molecular weight, is a vitamin K-dependent plasma coagulation factor. It consists of a complex asparagine glucose chain and is synthesized in the liver.…”

Section: Discussionmentioning

confidence: 99%

“…In fact, various sugarchain variants such as L3, P4, and P5 fractions are reported for AFP. 13,[30][31][32][33] Patients whose L3 fraction exceeds 15% were reported to have poor outcome as well as higher biological malignancy, 34,35 and in Japan, the AFP fraction is examined as a predictive factor for cancer recurrence. 35,36 Therefore, results of immunohistochemical staining could represent these abnormal AFP structures.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistologic study on the expressions of α-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma

Fujioka

Nakashima

et al. 2001

Hepatology

View full text Add to dashboard Cite

Sixty-eight cases of single hepatocellular carcinoma (HCC) with less than 3 cm of diameter were immunohistochemically examined for the expressions of ␣-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist II (PIVKA-II). In cancerous tissues, the expression rate was significantly higher for PIVKA-II (34 cases ␣-Fetoprotein (AFP) and protein induced by vitamin K absence or antagonist II (PIVKA-II) are well known as tumor markers of hepatocellular carcinoma (HCC), and their diagnostic usefulness has been confirmed. Serum levels of tumor markers generally increase along with the increase of tumor size, and most small HCCs at an early stage are not associated with the increases of AFP and PIVKA-II in the serum. In addition, serum AFP could increase slightly in patients with cirrhosis and chronic hepatitis resulting from active liver cell regeneration. Therefore, HCC specificity of serum AFP has been questioned. 1 However, since Breborowicz et al. 2 and Miyazaki et al. 3 demonstrated increases of lens culinaris agglutinin-reactive fraction of AFP in HCC at various levels, AFP that increases in hepatitis and cirrhosis became distinguishable from HCC-related AFP, and the examination of lens culinaris agglutinin-AFP fraction of serum AFP has been reported to be useful for HCC diagnosis. [4][5][6][7] On the other hand, PIVKA-II rarely increases with cirrhosis or chronic hepatitis, and possesses a high specificity to HCC. 8 However, because the serum PIVKA-II-positive rate is low in early-stage small HCC, PIVKA-II had been regarded as less important in clinical diagnosis. This opinion should be changed because of the introduction of a high-sensitivity kit (ED036, Eisai, Tokyo, Japan). 9 In the present study, expressions of AFP and PIVKA-II in the tissues of early-stage small HCC were immunohistochemically examined, and their relationships with tumor size, histologic grade, and serum AFP and PIVKA-II levels were investigated.[ PATIENTS AND MATERIALSAmong the early-stage small HCC nodules, which were surgically resected during 1995 and 1999 at Kurume University Hospital, 68 samples with single HCC nodule with less than 3.0 cm of diameter were subjected for the study. None of the 68 patients had previously received any treatments including transcatheter arterial embolization and percutaneous ethanol injection therapy. The age of the cases ranged from 41 to 86 years, with a mean of 62.7 Ϯ 8.3 (SD) years; there were 50 males and 18 females. All cases, except 1, were examined for virus markers, and 11 cases were hepatitis B surface antigenpositive; 47 cases were hepatitis C virus antibody-positive; 3 cases were positive to both hepatitis B surface antigen and hepatitis C virus antibody, and 6 cases were negative to both. Serum PIVKA-II was measured in 59 cases. Twenty-five of them were examined with a conventional test kit (Eitest MONOP II, Eisai, Co., Ltd.), and 100 mAU/mL was taken as the upper normal limit. The remaining 34 cases were examined with the high-sensitivity kit (ED036, Eisai), and 40 mAU/mL was...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Immunohistologic study on the expressions of α-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma

Fujioka

Nakashima

et al. 2001

Hepatology

View full text Add to dashboard Cite

show abstract

“…In China, 7.18% convenience, inexpensiveness, and accuracy (Taketa et al, 1990;Fujiyama et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Prognostic Value of Serum AFP, AFP-L3, and GP73 in Monitoring Short-term Treatment Response and Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation

Wang¹,

Li²,

Wang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Since then, an increasing number of studies report that PIVKAII is a useful tumour marker complementary to AFP in detecting HCC (Liebman et al, 1984;Taketa et al, 1990;Sato et al, 1993). Serum PIVKAII has attracted attention because of its very high specificity and lack of correlation with serum AFP levels.…”

mentioning

confidence: 99%

Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to α-fetoprotein

Zhang

et al. 2003

Br J Cancer

View full text Add to dashboard Cite

Serum protein induced by vitamin K absence or antagonist II (PIVKAII), hepatoma-specific band of serum gamma-glutamyl transferase (GGTII), and a-fetoprotein (AFP) levels were determined in 120 patients with hepatocellular carcinoma (HCC) and 90 patients with cirrhosis. The mean serum concentration of PIVKAII in HCC patients was higher than that in cirrhotic patients. A total of 53.3% of patients (64 out of 120) with HCC had PIVKAII levels above 40 mAU ml À1 . However, only 13 patients with cirrhosis had higher PIVKA II levels. Of 32 small HCC patients, 13 (40.6%) had PIVKAII values above 40 mAU ml À1 . An increased concentration of AFP (i.e. 20 ng ml À1 ) was observed in 70 out of 120 (58.3%) patients with HCC and in 33 out of 90 (36.7%) patients with cirrhosis. Positive GGTII was found in 74.0% (89 out of 120) cases of HCC (sensitivity), in 16 of 90 cases of cirrhosis, and 14 of 32 (43.8%) small HCC patients had GGTII positive. No significant correlation was found between serum levels of AFP and PIVKAII. Combining the information from PIVKAII, AFP, and GGTII significantly increases the sensitivity over AFP alone. PIVKAII and GGTII are useful tumour markers complementary to AFP for diagnosis of HCC.

show abstract

Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions

Cited by 208 publications

References 23 publications

Immunohistologic study on the expressions of α-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma

Immunohistologic study on the expressions of α-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma

Prognostic Value of Serum AFP, AFP-L3, and GP73 in Monitoring Short-term Treatment Response and Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation

Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to α-fetoprotein

Contact Info

Product

Resources

About